Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Deals

June 20 Quick Takes: FDA approves argenx’s subcutaneous Vyvgart

Plus: Clozel provides Idorsia cash lifeline, a clinical hold for Arcellx and updates from Vera, Denali, Delve Bio and Turbine

June 21, 2023 12:34 AM UTC

argenx SE (Euronext:ARGX; NASDAQ:ARGX) said it expects to launch Vyvgart Hytrulo next month, after FDA approved the subcutaneous version of myasthenia gravis drug Vyvgart efgartigimod alfa-fcab. The company is counting on Vyvgart Hytrulo to further drive uptake of an FCRN antibody that has helped lift the biotech’s valuation north of $22 billion. Vyvgart Hytrulo incorporates Enhanze delivery technology from Halozyme Therapeutics Inc. (NASDAQ:HALO). A competing anti-FCRN antibody, rozanolixizumab from UCB S.A. (Euronext:UCB), is under priority review by FDA.

CEO Jean-Paul Clozel is providing Idorsia Ltd. (SIX:IDIA) with a $75 million credit facility that will extend the biotech’s cash runway through July. The company said this month it has entered exclusive negotiations with an undisclosed party for a strategic transaction around its Asia-Pacific business, worth up to CHF400 million ($447.4 million). Idorsia markets Pivlaz clazosentan in Japan to treat vasospasm associated with aneurysmal subarachnoid hemorrhage; it markets Quviviq daridorexant in the U.S. and Europe to treat insomnia, and plans to seek its approval in Japan. The biotech was spun out of Actelion Ltd. when Johnson & Johnson (NYSE:JNJ) acquired it...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article